Vitamin E Supplementation for Treatment of Statin Induced Hepatocellular Damage: A Randomized, Double-Blind, Placebo- Controlled Trial

kamran Aghasadeghi; Somayeh  Nabavi; Fatemeh  Amirmoezi; Armin Attar

International Cardiovascular Research Journal

The Official Annually Journal of Cardiovascular Research Center, Shiraz University of Medical Sciences

Current Issue All Issues In Press Accepted Manuscripts Search

Journal Information Boards & Committees Indexing and Listing Sources Journal Metrics Publication Ethics and Publication Malpractice Statement Contact Us Support Reviewer and AE Registration Form

APC

Authors Guide Submit Manuscript

Vitamin E Supplementation for Treatment of Statin Induced Hepatocellular Damage: A Randomized, Double-Blind, Placebo- Controlled Trial

Author(s):

kamran Aghasadeghi¹,

Somayeh Nabavi²,

Fatemeh Amirmoezi ³,

Armin Attar^4,*

1Cardiovascular Research Center, Shiraz University of Medical Sciences, Shiraz, Iran

2Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran

3Hematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran

4Cardiovascular Research Center, TAHA Clinical Trial Group, Shiraz University of Medical Sciences, Shiraz, Iran

International Cardiovascular Research Journal:Vol. 12, issue 1; e62163

Published online:Mar 01, 2018

Article type:Research Article

Received:Feb 12, 2018

Accepted:Jan 20, 2018

How to Cite:kamran AghasadeghiSomayeh NabaviFatemeh Amirmoezi Armin AttarVitamin E Supplementation for Treatment of Statin Induced Hepatocellular Damage: A Randomized, Double-Blind, Placebo- Controlled Trial.Int Cardiovasc Res J.12(1):e62163.

Abstract

Background: Statin treatment can cause elevation of the liver aminotransferase levels in
1-3% of the patients with hypercholesterolemia. Previous studies indicate that vitamin E
plays a role in declining the increased levels of liver enzymes caused by fatty liver disease.
Objectives: We conducted this study to determine the effect of vitamin E on liver
aminotransferase levels in patients with elevated aminotransferase levels due to statin
consumption.
Materials and Methods: This study was a randomized, double-blind, placebo-controlled
trials. Eligible patients were those who developed elevated aminotransferase levels
after initiation of statin. They were randomized into the intervention group (vitamin
E capsules, 400 units/day for one month) and placebo group. Randomization was done
with permuted block sampling method with a 2:1 enrolment ratio. Study capsules
were allocated in separate packs blinded and labeled using a four-digit code. Alanine
aminotransferase (ALT) and asparate aminotransferase (AST) levels were checked in
the beginning and one month after the intervention. Comparison of the levels before and
after the intervention was done by paired sample T-test, and between group difference
was checked by independent sample T-test.
Results: A final number of 23 patients enrolled in this study (15 in the intervention and
8 in the control parallel groups). Baseline ALT and AST levels in both groups showed
no difference (74.3 ± 9.1 vs. 77.6 ± 17.5, P = 0.9; and 50 ± 8.2 vs. 43.3 ± 9.3, P = 0.34,
respectively). With consumption of vitamin E, ALT level was decreased from 77.6 ± 17.5
to 40.9 ± 13.4, showing a significant difference with placebo (treatment difference = -25.7,
P = 0.04). However, the reduction of asparate aminotransferase level from 43.3 ± 9.3 to
29.8 ± 5.9 was not significant compared to placebo (treatment difference = -1.5, P = 0.12).
Conclusions: Vitamin E therapy in patients with moderately elevated aminotransferase
levels (1.5-3 times than basal levels) due to statin consumption may be beneficial and can
reduce the asymptomatic hepatocellular damages.

Keywords

Atorvastatin

Hypercholesterolemia

Vitamin E

Fulltext

The full text is available in PDF.

References

1.
The references are available in PDF.

comments